Webinar: Recursion Pharmaceutical’s REC-994 Trial for CCM

On September 30th at 7 pm ET, 4 pm PT, please join Dr. Lisa Boyette, Recursion Pharmaceuticals’ Senior Director of Medical Affairs, who will be sharing details of the new REC-994 trial for cavernous angioma. REC-994 is the first industry-sponsored medicine to reach trials for our families, and we are thrilled to share information about the Phase 2 launch with our community. Dr. Boyette will provide an overview of clinical trials in general and will offer specifics of the REC-994 trial, including the nature of the medicine, where the first sites will be, and who and how many will be eligible to participate.

Register for this webinar